Frankfurt - Delayed Quote EUR

Takeda Pharmaceutical Company Limited (TKD.F)

26.19

-0.05

(-0.19%)

As of 8:11:42 AM GMT+2. Market Open.

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

OSAKA, Japan, May 08, 2025--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management.

Business Wire 2 hours ago

TAK

TKPHF
Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 17 hours ago

TAK
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 19 hours ago

TAK
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

BANNOCKBURN, Ill., May 05, 2025--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of

Business Wire 2 days ago

TAK

TKPHF
TAK or DSNKY: Which Is the Better Value Stock Right Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks 5 days ago

TAK

4568.T
Stocks to watch this week: Palantir, TSMC, Novo Nordisk and JD Wetherspoon

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 3 days ago

ARM

NXGPF

NXGPY
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice

Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 7 days ago

TAK
Best Value Stocks to Buy for April 30th

SKM, TAK and PHIN made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 30, 2025.

Zacks 7 days ago

SKM

TAK
Best Income Stocks to Buy for April 30th

SKM, TAK and SONY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 30, 2025.

Zacks 7 days ago

SKM

TAK
New Strong Buy Stocks for April 30th

DB, SPOT, SONY, CIVB and TAK have been added to the Zacks Rank #1 (Strong Buy) List on April 30, 2025.

Zacks 8 days ago

SPOT

TAK
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 16 days ago

TAK
TAK vs. DSNKY: Which Stock Is the Better Value Option?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks 21 days ago

4568.T

TAK
NMPA approves BBM and Takeda China’s haemophilia B therapy

Takeda China handles the therapy’s commercialisation in mainland China, Macau and Hong Kong.

Pharmaceutical Technology 26 days ago

TAK
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Drugmakers have said they’re still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.

The Wall Street Journal 28 days ago

TAK

TKPHF

DSKYF
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

TAK
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks last month

4568.T

TAK
Takeda Canada says Health Canada expands marketing authorization for HyQvia

Takeda (TAK) Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with intravenous immunoglobulin to prevent relapse of neuromuscular disability and impairment in adults. HyQvia is the only up to once monthly subcutaneous immunoglobulin infusion to treat CIDP in Canada and can be administered by a healthcare professional or self-administered with training, so patien

TipRanks last month

TAK

TKPHF
Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) for chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with intravenous immunoglobulin (IVIG) to prevent relapse of neuromuscular disability and impairment in adults.1

CNW Group last month

TAK

TKPHF
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

TAK
Takeda’s $770M deal deepens Big Pharma’s omics push

The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.

Pharma Voice last month

TAK

Performance Overview

Return	TKD.F	Nikkei 225 (^N225)
YTD	-141.68%	-7.43%
1-Year	-84.99%	-3.33%
3-Year	-99.49%	+36.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Takeda Pharmaceutical Company Limited (TKD.F)

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Stocks to watch this week: Palantir, TSMC, Novo Nordisk and JD Wetherspoon

Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice

Best Value Stocks to Buy for April 30th

Best Income Stocks to Buy for April 30th

New Strong Buy Stocks for April 30th

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

NMPA approves BBM and Takeda China’s haemophilia B therapy

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

Takeda Canada says Health Canada expands marketing authorization for HyQvia

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

Takeda’s $770M deal deepens Big Pharma’s omics push

Performance Overview